| Literature DB >> 27473316 |
Nimna S Ranatunga1, Susan L Forsburg2.
Abstract
The minichromosome maintenance (MCM) complex is the conserved helicase motor of the eukaryotic replication fork. Mutations in the Mcm4 subunit are associated with replication stress and double strand breaks in multiple systems. In this work, we characterize a new temperature-sensitive allele of Schizosaccharomyces pombe mcm4+ Uniquely among known mcm4 alleles, this mutation causes sensitivity to the alkylation damaging agent methyl methanesulfonate (MMS). Even in the absence of treatment or temperature shift, mcm4-c106 cells show increased repair foci of RPA and Rad52, and require the damage checkpoint for viability, indicating genome stress. The mcm4-c106 mutant is synthetically lethal with mutations disrupting fork protection complex (FPC) proteins Swi1 and Swi3. Surprisingly, we found that the deletion of rif1+ suppressed the MMS-sensitive phenotype without affecting temperature sensitivity. Together, these data suggest that mcm4-c106 destabilizes replisome structure.Entities:
Keywords: DNA replication; MCM complex; MMS; checkpoint; fission yeast; fork protection complex
Mesh:
Substances:
Year: 2016 PMID: 27473316 PMCID: PMC5068930 DOI: 10.1534/g3.116.033571
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Strains used in this study
| Strain | Genotype | Source |
|---|---|---|
| FY 7 | Our stock | |
| FY 527 | Our stock | |
| FY 528 | Our stock | |
| FY 261 | Our stock | |
| FY 784 | Our stock | |
| FY 4241 | Takuro Nakagawa | |
| FY 4311 | Our stock | |
| FY 4310 | Our stock | |
| FY 5942 | This work | |
| FY 3395 | Our stock | |
| FY 6126 | Our stock | |
| FY 6038 | Our stock | |
| FY 6039 | Our stock | |
| FY 6040 | This work | |
| FY 6041 | This work | |
| FY 6042 | This work | |
| FY 6043 | This work | |
| FY 6044 | This work | |
| FY 6052 | This work | |
| FY 6053 | This work | |
| FY 6054 | This work | |
| FY 6055 | This work | |
| FY 6077 | This work | |
| FY 6078 | This work | |
| FY 6079 | This work | |
| FY 6080 | This work | |
| FY 6123 | This work | |
| FY 6146 | This work | |
| FY 6147 | This work | |
| FY6238 | This work | |
| FY 6248 | This work | |
| FY 6266 | This work | |
| FY 6281 | This work | |
| FY 6308 | This work | |
| FY 6309 | This work | |
| FY 6751 | This work | |
| FY 6777 | This work | |
| FY 6778 | This work | |
| FY 6779 | This work | |
| FY 6780 | This work | |
| FY 6961 | This work | |
| FY 7045 | This work | |
| FY 7047 | This work | |
| FY 7048 | This work | |
| FY 7165 | This work | |
| FY 7166 | This work | |
| FY 7461 | This work | |
| FY 7462 | This work | |
| FY7611 | This work | |
| FY 7802 | This work | |
| FY 7922 | This work | |
| FY 7923 | This work | |
| FY 7924 | This work | |
| FY 7925 | This work | |
| FY 7926 | This work | |
| FY 3664 | Our Stock | |
| FY 8000 | This work | |
| FY 8015 | This work | |
| FY 8016 | This work | |
| FY 8017 | This work | |
| FY 8018 | This work | |
| FY 7689 | Our stock/Bioneer derived | |
| FY 7690 | Our stock/Bioneer derived | |
| FY 8107 | This work | |
| FY 7808 | This work | |
| FY 8108 | This work | |
| FY 5014 | Our stock | |
| FY 5270 | Our stock | |
| FY 3124 | Our stock | |
| FY 4415 | Our stock | |
| FY 277 | Hiroto Okayama | |
| FY 5401 | Our stock | |
| FY 4937 | Our stock | |
| FY 5142 | Mathew O’Connell | |
| FY 4938 | Our stock | |
| FY 2050 | Our stock | |
| FY 5260 | Our stock | |
| FY 5625 | Our stock/Bioneer derived | |
| FY 4742 | Our stock | |
| FY 4611 | Our stock | |
| FY 1163 | Our stock | |
| FY 3845 | Our stock | |
| FY 1257 | Shelly Sazer | |
| FY 5583 | Our stock/Bioneer derived | |
| FY 3884 | Mathew O’Connell | |
| FY 2389 | Junko Kanoh | |
| FY5555 | Our stock | |
| FY 4581 | Our stock | |
| FY4159 | Our stock | |
| FY1191 | Dwight Williams | |
| FY 1203 | Greg Freyer | |
| FY 1318 | Our Stock | |
| FY 1159 | Our stock | |
| FY 3588 | Zach Cande/XieTang | |
| FY 3227 | Our stock | |
| FY 3228 | Our Stock | |
| FY 7995 | This work | |
| FY 5787 | Our stock | |
| FY 7653 | Our stock/Bioneer derived | |
| FY 8017 | This work/Bioneer derived | |
| FY 8110 | This work | |
| FY 8111 | This work | |
| FY 2711 | Our stock | |
| FY 3999 | Our stock | |
| FY 8197 | This work | |
| FY 1110 | Our stock |
Figure 1Viability of mcm4 mutants at 36° and in MMS. (A) Temperature sensitivity evaluated by 1:5 serially diluted cultures plated on YES (rich media) and grown at the indicated temperatures. Wild-type (FY 528), rad3∆ (FY1106), mcm4 chaos (FY 3664), mcm4-dg (FY 3395), mcm4-4SA (FY5251), mcm4 2-73∆ (FY 5688), mcm4-c84 (FY4310), mcm4-c106 (FY 4311), and mcm4-M68 (FY784). (B) MMS sensitivity evaluated by 1:5 serially diluted cultures plated on YES (rich media) as control and 0.005% MMS at 25°. MMS, methyl methanesulfonate; YES, yeast extract + supplements.
Figure 2mcm4-c106 has a defect in replication at permissive temperature. (A) WT (FY 528), mcm4-M68 (FY784), and mcm4-c106 (FY 4311) strains transformed with pUR19N plasmid plated on media lacking uracil. Colonies observed after 7 d of growth at 25°. (B) Colonies isolated from transformation (A), streaked to single colonies on media lacking uracil, and grown at 25° for 5 d. (C) Percentage of colonies observed posttransformation of 200 ng/µl pUR19N plasmid relative to the wild type. Error bars represent 95% C.I. of the mean. WT, wild-type.
Figure 3Replication dynamics in mcm4-c106 at 36° and MMS. (A) Relative viability of cultures during incubation at 36°. The indicated cultures were plated at 25° on YES, and viability was compared to the starting culture. (B) Bulk DNA content measured by flow cytometry of Sytox Green labeled cells. Cells were synchronized in G1 by nitrogen starvation and released to 25°, 36°, and 0.01% MMS nitrogen-containing medium. WT (FY261), mcm4-c106 (FY 4311). The indicated times correspond to the time after release. (C) Pulsed field gel electrophoresis (PFGE) analysis in each genotype in untreated asynchronous (AS) cells, after 4 hr 36° (4 hr) and after 2hr release to 25° (R). WT (FY 528), mcm4-M68 (FY784), and mcm4-c106 (FY 4311). S. pombe chromosomes are indicated on the left. (D) Relative viability of cultures during incubation with 0.01% MMS. The indicated cultures were plated at 25° on YES plates and the viability was compared to the starting culture. MMS, methyl methanesulfonate; WT, wild-type; YES, yeast extract + supplements.
Figure 4Mcm4 protein levels and Chk1 phosphorylation in response to MMS and 36°. (A) Evidence for Chk1 activation following 0.01% MMS for 4 hr. Chk1 mobility in SDS-PAGE was used as a proxy for phosphorylation. Lanes 1 and 2, mcm4-c106 (FY 4311); lanes 3 and 4, chk1-HA (FY 4611); lanes 5 and 6 mcm4-c106 chk1-HA (FY6281). Arrow indicates phosphoshift. (B) Activation of Chk1 following 4 hr incubation at 36°. Lanes 1 and 2, mcm4-c106 (FY 4311); lanes 3 and 4, chk1-HA (FY 4611); lanes 5 and 6, mcm4-c106 chk1HA (FY6281). (C) Mcm4 protein levels following MMS treatment. (D) Mcm4 protein levels following incubation at 36°. MMS, methyl methanesulfonate; PCNA, proliferating cell nuclear antigen.
Sensitivity to MMS of double mutants of genes involved in different aspects of the cell cycle
| Category | Mutant | Function | Phenotype with c106 | MMS Phenotype |
|---|---|---|---|---|
| Checkpoint | Kinase; S phase/replication checkpoint | Viable | > | |
| Checkpoint | Kinase; G2/damage checkpoint | Synthetic lethal | ND | |
| Checkpoint | Spindle checkpoint | Viable | = | |
| Checkpoint | Checkpoint protein | Synthetic lethal | ND | |
| Checkpoint | Kinase | Synthetic lethal | ND | |
| Cohesion | Helicase | Viable | > | |
| Cohesion | Cohesin protein | Viable | = | |
| Replication | Part of the FPC/cohesion | Sick | ND | |
| Replication-FPC | Replication mutants/FPC | Synthetic lethal | ND | |
| Replication-FPC | Replication mutants/FPC | Synthetic lethal | ND | |
| Replication-FPC | Replication mutants/FPC | Synthetic lethal | ND | |
| Replication | DDK kinase | Synthetic lethal | ND | |
| Replication | DDK kinase | Viable/sick | ND | |
| Replication, genome stability | Rif1 antagonist of DDK | Viable | rescued | |
| Genome stability | Genome stability | Viable | ||
| Replication clamp loader | Cohesion-specific clamp loader | Viable < temp | ||
| Replication clamp loader | Cohesion-specific clamp loader | Viable < temp | ||
| Genome stability | Helicase; genome stability | Viable | ||
| Genome stability | Holiday junction resolvase | Sick | = | |
| Genome stability | Helicase; recombination antagonist | Viable | > | |
| Genome stability | Helicase; recombination regulator | Viable | > | |
| Repair | Eso1- Polη fusion; deletes polymerase domain. Error prone repair | Viable | ≤ | |
| Repair | Exonuclease I | Viable | = | |
| Repair | Ubiquitin ligase; error free repair | Viable | > | |
| Repair | PCNA; ubiquitin site mutant | Viable | = | |
| Repair | Viable | |||
| Repair | Homologous recombination | Viable | = | |
| Repair | Ubiquitin ligase-helicase; error free repair | Viable | ||
| Repair | Deoxycytidyl transferase; error prone repair | Viable | ≥ | |
| Repair | Viable | |||
| Repair | PCNA ubiquitin ligase | Viable | = | |
| Repair | Ubiquitin ligase; error free | Viable | > | |
| Heterochromatin protein | Viable | = | ||
| S phase cyclin | Viable | ≤ | ||
| Transcription termination | Viable < temp | = | ||
| Heterochromatin protein | Viable | = | ||
| Viable/slow growing | ND | |||
| Viable | ND | |||
| Synthetic lethal | NA | |||
| Component of the GINS replication complex | Viable | |||
| Viable | ND | |||
| Synthetic lethal | NA |
Double mutant phenotypes between mcm4-c106 and other mutants in the indicated classes. MMS, methyl methanesulfonate; ND, Not Determined; FPC, fork protection complex; DDK, Dbf4-dependent kinase; PCNA, proliferating cell nuclear antigen; NA, Not Applicable.
Phenotype: viable means no change in temperature sensitivity. Synthetic lethal is dead at temperatures. Sick shows reduced growth rate at all temperatures.
MMS phenotype is determined relative to the most sensitive parent (indicated) being > (greater sensitivity), < (less sensitive), or = (equal sensitivity).
Figure 5Accumulation of repair foci in mcm4-c106 in response to MMS and temperature. (A) Membrane (ccr1N-mCherry), RPA-CFP (blue), and Rad52-YFP (yellow) focus patterns during treatment at restrictive temperature (36°) and release. Multiple small foci were observed with the mcm4-c106 that remained after release. RPA and Rad52 focus patterns during treatment with 0.01% MMS for 4 hr and release for 2 hr. Multiple small foci were observed during treatment and release in the mcm4-c106 compared to the wild type. Scale 10 µm. (B) Quantification of Rad11 foci of wild-type and mcm4-c106 during 36° treatment and release. (C) Quantification of Rad52 foci of wild-type and mcm4-c106 during 36° treatment and release. (D) Quantification of Rad11 foci of wild-type and mcm4-c106 during 4 hr MMS treatment and release. (E) Quantification of Rad52 foci of wild-type and mcm4-c106 during 4 hr MMS treatment and release. Two or more independent experiments were pooled and a 95% C.I. was calculated. Async, asynchronous; MMS, methyl methanesulfonate.
Figure 6rif1∆ rescues the mcm4-c106 MMS phenotype. (A) Temperature sensitivity evaluated by strains grown overnight at 25°, 1:5 serially diluted, and plated on YES (rich media) at 25° as control, and 32° and 36° to observe the temperature effect. (B) and (C) MMS sensitivity evaluated by strains grown overnight at 25°, 1:5 serially diluted, and plated on YES (rich media) as control, and 0.003% and 0.005% MMS at 25°. MMS, methyl methanesulfonate; YES, yeast extract + supplements.
Figure 7mcm4-c106 interactions with alternative replication factor C (RFC). (A) mcm4-c106 combined with RFCCtf18∆ and RFCCtf8∆. Representative response to temperature was assayed by serial dilutions. Strains were grown overnight at 25°, 1:5 serially diluted, and plated on YES (rich media) as the control, and 32° and 36° to observe the temperature effect. (B) Representative response to MMS assessed by serial diluted samples plated on the indicated concentrations of MMS. (C) chl1∆ mcm4-c106 and (D) cohesion subunit rad21-K1 mcm4-c106 effects on MMS. MMS, methyl methanesulfonate; YES, yeast extract + supplements.